U.S. Markets closed

Chimeric Therapeutics Limited (CHM.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
0.1350-0.0100 (-6.90%)
At close: 03:58PM AEST

Chimeric Therapeutics Limited

62 Lygon Street
Level 3
Carlton, VIC 3053
61 3 9824 5254

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Ms. Jennifer ChowCEO, MD & Director1.23MN/AN/A
Dr. Li RenVP of Technical OperationsN/AN/AN/A
Mr. Eliot BourkChief Bus. Officer & Head of External InnovationN/AN/AN/A
Mr. Kelly R. ThornburgVP & Head of QualityN/AN/A1963
Mr. Jason B. Litten M.D.Chief Medical OfficerN/AN/A1974
Mr. Phillip Hains B Bus, C.A., CA, M.B.A., MBASec.N/AN/A1961
Mr. Nathan Jong C.A.Company Sec.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Chimeric Therapeutics Limited researches, develops, and commercializes cell therapies for cancer in Australia. The company develops CLTX CAR T cell therapy that is in Phase I clinical study for Glioblastoma; and CDH17 CAR T, which is in preclinical study for neuroendocrine tumours, as well as colorectal, pancreatic, and gastric cancer. It has a strategic partnership with OncoBay Clinical for the development program of CLTX CAR T. The company was incorporated in 2020 and is based in Carlton, Australia.

Corporate Governance

Chimeric Therapeutics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.